On March 18, 2015, KEI, KEI Europe, and Essential Inventions submitted proposals for global voluntary licences for all patents necessary for hepatitis C (HCV) medicines to five drug companies — AbbVie, Bristol-Myers Squibb, Gilead, Janssen, and Merck.
Monday, 30 April 2007 “The sanctioning of countries for using legitimate and important flexibilities in the TRIPS agreement brings shame to all U.S. citizens who are increasingly seen in Thailand and elsewhere as bullies and hypocrites.” The following is the… Continue Reading
On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). … Continue Reading
Knowledge Ecology International: Q&A Session on Thai White Paper (Facts and Evidences on the 10 Burning Issues Related to the Government Use of Patents on Three Patented Essential Drugs in Thailand) Geneva, Switzerland 8 March 2007 Thiru Balasubramaniam On Thursday,… Continue Reading
R 281104Z JUN 05 – June 28, 2005FM AMEMBASSY BRASILIATO SECSTATE WASHDC 1902SUBJECT: BRAZIL GIVES ABBOTT TEN DAYS BEFORE BREAKING PATENT 1. (U) SENSITIVE BUT UNCLASSIFIED 2. (U) Summary. On Friday June 24, the GoB announced a declaration of “public… Continue Reading
R 031944Z JUN 05 – June 3, 2005FROM: American Embassy BrasiliaTO: Secretary of State, Washington, D.C.SUBJECT: AMBASSADOR MEETS WITH U.S. PHARMACEUTICAL FIRMS THREATENED WITH LICENSING 1. (SBU) Summary. On May 24 and 25, U.S. pharmaceutical companies Gilead Sciences, Abbott Laboratories,… Continue Reading